Showing 4271-4280 of 9848 results for "".
- Soliton, US Navy to Collaborate on Study of RAP for Fibrotic Scarshttps://practicaldermatology.com/news/soliton-us-navy-to-collaborate-on-study-of-rap-for-fibrotic-scars/2460670/Soliton, Inc. will collaborate with the US Navy to conduct a multi-treatment proof-of-concept clinical study to evaluate the safety and efficacy of multiple treatments with Soliton's Rapid Acoustic Pulse (RAP) device for the improvement in the appearance of fibrotic scars. The study
- Pulse Biosciences Scores CE Mark for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-ce-mark-for-cellfx-system/2460666/Pulse Biosciences, Inc. received CE mark for the CellFXSystem. The Company can now proceed with its planned controlled launch of the CellFX System to medical practices within the European Union (EU) for the treatment of general dermatologic conditions, including sebaceous hyperplasia (S
- Candela Launches Frax Pro Systemhttps://practicaldermatology.com/news/candela-launches-frax-pro-system/2460665/Candela’s Frax Pro system is now available. This platform features Frax 1550 and the novel Frax 1940 applicators. The Frax 1940 handpiece delivers a 1940 nm wavelength laser beam for a shallow, epidermal approach, with focal reach extending to approximately 200 μm in
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://practicaldermatology.com/news/ajinomoto-bio-pharma-services-and-revance-therapeutics-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2460641/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.
- DermOQ Oxygen Lab Completes Purchase of ECHO2 Plus Oxygen Facial Treatment Product Line from Skin Products, Inc.https://practicaldermatology.com/news/dermoq-oxygen-lab-completes-purchase-of-echo2-plus-oxygen-facial-treatment-product-line-from-skin-products-inc/2460640/DermOQ Oxygen Lab closed their acquisition of ECHO2 Plus Oxyceuticals oxygen facial treatment product line from Skin Products, Inc. for an undisclosed amount. "ECHO2 Plus is a 45-minute facial treatment offered at physician's offices, spas, hotels and corporate custom
- Aerolase Introduces Skin of Color Forumhttps://practicaldermatology.com/news/aerolase-introduces-skin-of-color-forum/2460639/Aerolase Corp. is launching a Skin of Color Forum (SOCF). "This Forum is much needed and transformative. It's been rewarding to work alongside Aerolase to shape its leadership in advancing skin of color dermatology," sa
- For Upper Facial Lines, DaxibotulinumtoxinA Succeeds in Phase 2https://practicaldermatology.com/news/for-upper-facial-lines-daxibotulinumtoxina-succeeds-in-phase-2/2460637/Topline efficacy and safety results from the phase 2 multicenter, open-label study of Revance's investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, show high levels of patient satisfaction. The 36-week study enrolled 48
- AbbVie’s Rinvoq Performs Well in Head-to-Head Phase 3b AD Studyhttps://practicaldermatology.com/news/abbvies-rinvoq-performs-well-in-head-to-head-phase3b-ad-study/2460630/Topline results from the phase 3b “Heads Up” study show that a greater proportion of subjects treated with AbbVie’s Rinvoq (upadacitinib 30mg, once daily) achieved at least a 75 percent improvement in the Eczema Area Severity Index (EASI 75) at week 16, compared to dupilumab (30
- Colleen Goggins Joins ZO Skin Health's Board Of Directorshttps://practicaldermatology.com/news/colleen-goggins-joins-zo-skin-healths-board-of-directors-following-majority-investment-by-blackstone/2460624/Colleen Goggins is joining ZO Skin Health’s board of directors. This follows the recent acquisition of a majority stake in the business in October by funds managed by Blackstone Tactical Opportunities. As a partner and counsellor to a large variety of bu